Fuji Oozx Inc. (TYO:7299)
Japan · Delayed Price · Currency is JPY 1,444.00
+5.00 (0.35%)
Aug 1, 2025, 3:30 PM JST
Blueprint Medicines Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 26,263 | 25,544 | 23,381 | 21,606 | 22,269 | 19,121 | Upgrade | |
Revenue Growth (YoY) | 9.67% | 9.25% | 8.21% | -2.98% | 16.46% | -16.11% | Upgrade |
Cost of Revenue | 19,980 | 19,435 | 18,442 | 17,960 | 17,711 | 15,947 | Upgrade |
Gross Profit | 6,283 | 6,109 | 4,939 | 3,646 | 4,558 | 3,174 | Upgrade |
Selling, General & Admin | 3,503 | 3,398 | 3,252 | 2,716 | 2,929 | 2,396 | Upgrade |
Research & Development | 53 | 53 | 59 | 60 | 58 | 66 | Upgrade |
Other Operating Expenses | 13 | 13 | - | - | - | - | Upgrade |
Operating Expenses | 3,597 | 3,492 | 3,312 | 2,776 | 2,987 | 2,460 | Upgrade |
Operating Income | 2,686 | 2,617 | 1,627 | 870 | 1,571 | 714 | Upgrade |
Interest Expense | -76 | -75 | -61 | -86 | -67 | -79 | Upgrade |
Interest & Investment Income | 24 | 29 | 52 | 36 | 25 | 7 | Upgrade |
Currency Exchange Gain (Loss) | -378 | -285 | 242 | 205 | 166 | -37 | Upgrade |
Other Non Operating Income (Expenses) | 53 | 62 | 83 | 65 | 117 | 299 | Upgrade |
EBT Excluding Unusual Items | 2,309 | 2,348 | 1,943 | 1,090 | 1,812 | 904 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 38 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -11 | -8 | -15 | -41 | -28 | -79 | Upgrade |
Asset Writedown | - | - | -183 | -136 | -161 | -4 | Upgrade |
Other Unusual Items | 363 | 212 | - | - | - | - | Upgrade |
Pretax Income | 2,661 | 2,552 | 1,783 | 913 | 1,623 | 821 | Upgrade |
Income Tax Expense | 726 | 989 | -176 | 296 | 645 | 204 | Upgrade |
Earnings From Continuing Operations | 1,935 | 1,563 | 1,959 | 617 | 978 | 617 | Upgrade |
Minority Interest in Earnings | -22 | -17 | -28 | -23 | 7 | -4 | Upgrade |
Net Income | 1,913 | 1,546 | 1,931 | 594 | 985 | 613 | Upgrade |
Net Income to Common | 1,913 | 1,546 | 1,931 | 594 | 985 | 613 | Upgrade |
Net Income Growth | 8.45% | -19.94% | 225.08% | -39.70% | 60.69% | 59.22% | Upgrade |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
Shares Change (YoY) | -0.71% | -0.60% | - | -0.00% | -0.00% | -0.00% | Upgrade |
EPS (Basic) | 187.85 | 151.46 | 188.04 | 57.84 | 95.91 | 59.69 | Upgrade |
EPS (Diluted) | 187.85 | 151.46 | 188.04 | 57.84 | 95.91 | 59.69 | Upgrade |
EPS Growth | 9.23% | -19.45% | 225.09% | -39.69% | 60.69% | 59.22% | Upgrade |
Free Cash Flow | - | 1,281 | 2,764 | 1,127 | 3,480 | 3,444 | Upgrade |
Free Cash Flow Per Share | - | 125.50 | 269.15 | 109.74 | 338.87 | 335.35 | Upgrade |
Dividend Per Share | 52.000 | 52.000 | 50.000 | 26.000 | 26.000 | 13.000 | Upgrade |
Dividend Growth | 4.00% | 4.00% | 92.31% | - | 100.00% | -40.91% | Upgrade |
Gross Margin | 23.92% | 23.92% | 21.12% | 16.88% | 20.47% | 16.60% | Upgrade |
Operating Margin | 10.23% | 10.24% | 6.96% | 4.03% | 7.05% | 3.73% | Upgrade |
Profit Margin | 7.28% | 6.05% | 8.26% | 2.75% | 4.42% | 3.21% | Upgrade |
Free Cash Flow Margin | - | 5.01% | 11.82% | 5.22% | 15.63% | 18.01% | Upgrade |
EBITDA | 5,114 | 5,030 | 3,981 | 3,187 | 4,178 | 3,081 | Upgrade |
EBITDA Margin | 19.47% | 19.69% | 17.03% | 14.75% | 18.76% | 16.11% | Upgrade |
D&A For EBITDA | 2,428 | 2,413 | 2,354 | 2,317 | 2,607 | 2,367 | Upgrade |
EBIT | 2,686 | 2,617 | 1,627 | 870 | 1,571 | 714 | Upgrade |
EBIT Margin | 10.23% | 10.24% | 6.96% | 4.03% | 7.05% | 3.73% | Upgrade |
Effective Tax Rate | 27.28% | 38.75% | - | 32.42% | 39.74% | 24.85% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.